In breast cancer, concurrent amplification of the CDK12 and ERBB2 genes has been described in ductal type NST carcinomas and in association with poor prognosis, worse response to anti‐HER2 treatment and also resistance to endocrine therapy [24, 25, 26, 27, 28]. Here, ERBB2 is linked to breast carcinoma.